MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Protalix BioTherapeutics, Inc. (NYSE:PLX)*
Organization & Developments: Protalix BioTherapeutics
Parents
Protalix BioTherapeutics, Inc. (NYSE:PLX)*
Children
2018: Protalix Should Be Looked At After Positive Ulcerative Colitis Data - Protalix BioTherapeutics, Inc (NYSEMKT:PLX)
2020: FDA Decision For Protalix Postponed Due To Covid, But Fundamentals Remain Strong
2020: Protalix Should Go Higher If FDA Approves Fabry Disease Therapy
2020: Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant
2020: Protalix: Investors Should Bear 'Balance' In Mind When Considering The Fabry BLA
2021: FDA Issues CRL for Protalix and Chiesi's Fabry Disease Drug
2021: Lacking BALANCE, Protalix Tumbles
2021: Protalix BioTherapeutics: CRL Could Not Have Come At A Worse Time
2023: Protalix BioTherapeutics: Fiscal Challenges And Gout Therapy Prospects_ seekingalpha.com
2023: Protalix, Chiesi challenge Sanofi with EU approval for Fabry disease med as FDA decision looms
2024: Protalix BioTherapeutics' Phase 1 Data Bolsters Gout Aspirations (Rating Upgrade)_seekingalpha.com
Jumps
Finance & Acquisitions: Protalix BioTherapeutics
Key People: Protalix BioTherapeutics